RLAY Stock Analysis: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$9.33
-0.28 (-2.86%)
▼
5d:
-5.04%
30d:
-9.11%
90d:
+8.94%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
RLAY is down 8.1% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 11,600 OI. Call ratio: 100% View Scanner →
Strength: 9.1/10
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RLAY shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RLAY shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $9.32, which is considered fair relative to its 30-day fair value range of $9.22 to $10.31.
Technical Outlook: Technically, RLAY is in a strong uptrend. The price is currently testing key support at $9.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.09 (+78.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RLAY is in a strong uptrend. The price is currently testing key support at $9.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.09 (+78.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$9.22 -
$10.31
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 78.0% below Wall St target ($17.09)
- CAUTION: Recommendation downgraded due to -5.0% 5-day decline
Fair Price Analysis
30-Day Fair Range
$9.22 -
$10.31
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$9.27
Resistance Level
$10.75
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.20
Wall Street Target
$17.09
(+78.0%)
Revenue Growth (YoY)
-23.3%
Share & Embed Analysis
Last updated: March 30, 2026 2:53 PM ET
Data refreshes hourly during market hours. Next update: 3:53 PM
Data refreshes hourly during market hours. Next update: 3:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Peter Rahmer
SELL
1354 shares
2026-01-28
Thomas Catinazzo
SELL
1695 shares
2026-01-28
Donald A Bergstrom
SELL
2686 shares
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 49 HOLD |
